The artificial intelligence (AI) capabilities of the new software reportedly facilitate scanning times that are three times faster than conventional magnetic resonance image (MRI) scanners.
Offering the potential of enhanced resolution with accelerated scan times for magnetic resonance imaging (MRI), SmartSpeed (Philips), an emerging artificial intelligence (AI)-enabled software, has garnered FDA 510(k) clearance.
In comparison to other MRI modalities, Philips said the addition of SmartSpeed to the company’s Compressed SENSE MR acceleration engine offers a threefold reduction in MRI scanning time and increases image resolution up to 65 percent.
“Philips’ AI-based SmartSpeed reconstruction is the new benchmark among acceleration techniques for us. It improves on the company’s existing Compressed SENSE (MR acceleration engine) in all aspects and allows a reduction in scan times with excellent image quality and diagnostic confidence,” noted Grischa Bratke, MD, who is affiliated with the Department of Radiology at the University Hospital of Cologne in Germany.
Philips noted that application of the AI reconstruction algorithm with SmartSpeed at the front end of the MR signal facilitates a high signal-to-noise ratio that enhances image quality and enables small lesion detection.
Adding that the SmartSpeed software can be applied in 97 percent of current clinical protocols, Philips emphasized the utility of the software in quantitative MR imaging including mapping of the heart, liver, and brain.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.